Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

p-Cresyl sulfate and indoxyl sulfate in pediatric patients on chronic dialysis

  • Hyun, Hye Sun (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Paik, Kyung Hoon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Cho, Hee Yeon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2012.09.10
  • Accepted : 2012.10.24
  • Published : 2013.04.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Indoxyl sulfate and p-cresyl sulfate are important protein-bound uremic retention solutes whose levels can be partially reduced by renal replacement therapy. These solutes originate from intestinal bacterial protein fermentation and are associated with cardiovascular outcomes and chronic kidney disease progression. The aims of this study were to investigate the levels of indoxyl sulfate and p-cresyl sulfate as well as the effect of probiotics on reducing the levels of uremic toxins in pediatric patients on dialysis. Methods: We enrolled 20 pediatric patients undergoing chronic dialysis; 16 patients completed the study. The patients underwent a 12-week regimen of VSL#3, a high-concentration probiotic preparation, and the serum levels of indoxyl sulfate and p-cresyl sulfate were measured before treatment and at 4, 8, and 12 weeks after the regimen by using fluorescence liquid chromatography. To assess the normal range of indoxyl sulfate and p-cresyl sulfate we enrolled the 16 children with normal glomerular filtration rate who had visited an outpatient clinic for asymptomatic microscopic hematuria that had been detected by a school screening in August 2011. Results: The baseline serum levels of indoxyl sulfate and p-cresyl sulfate in the patients on chronic dialysis were significantly higher than those in the children with microscopic hematuria. The baseline serum levels of p-cresyl sulfate in the peritoneal dialysis group were significantly higher than those in the hemodialysis group. There were no significant changes in the levels of these uremic solutes after 12-week VSL#3 treatment in the patients on chronic dialysis. Conclusion: The levels of the uremic toxins p-cresyl sulfate and indoxyl sulfate are highly elevated in pediatric patients on dialysis, but there was no significant effect by probiotics on the reduction of uremic toxins in pediatric dialysis patients. Therefore, studies for other medical intervention to reduce uremic toxins are also necessary in pediatric patients on dialysis.

Keywords

References

  1. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-43. https://doi.org/10.1046/j.1523-1755.2003.00924.x
  2. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815-23.
  3. Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R. Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 2002;40:339-47. https://doi.org/10.1053/ajkd.2002.34518
  4. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P. Protein-bound toxins: update 2009. Semin Dial 2009;22:334-9. https://doi.org/10.1111/j.1525-139X.2009.00576.x
  5. Meyer TW, Hostetter TH. Uremia. N Engl J Med 2007;357:1316-25. https://doi.org/10.1056/NEJMra071313
  6. Meijers BK, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. p- Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:1932-8. https://doi.org/10.2215/CJN.02940509
  7. Evenepoel P, Meijers BK, Bammens BR, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney Int Suppl 2009;(114):S12-9.
  8. Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH. Serum proteinbound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrol Dial Transplant 2010;25:3693-700. https://doi.org/10.1093/ndt/gfq251
  9. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996;74:349-55. https://doi.org/10.1159/000189334
  10. Nakabayashi I, Nakamura M, Kawakami K, Ohta T, Kato I, Uchida K, et al. Effects of synbiotic treatment on serum level of p- cresol in haemodialysis patients: a preliminary study. Nephrol Dial Transplant 2011;26:1094-8. https://doi.org/10.1093/ndt/gfq624
  11. de Loor H, Meijers BK, Meyer TW, Bammens B, Verbeke K, Dehaen W, et al. Sodium octanoate to reverse indoxyl sulfate and p- cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. J Chromatogr A 2009;1216:4684-8. https://doi.org/10.1016/j.chroma.2009.04.015
  12. Pham NM, Recht NS, Hostetter TH, Meyer TW. Removal of the protein-bound solutes indican and p- cresol sulfate by peritoneal dialysis. Clin J Am Soc Nephrol 2008;3:85-90. https://doi.org/10.2215/CJN.02570607
  13. Evenepoel P, Bammens B, Verbeke K, Vanrenterghem Y. Superior dialytic clearance of beta(2)-microglobulin and p- cresol by highflux hemodialysis as compared to peritoneal dialysis. Kidney Int 2006;70:794-9. https://doi.org/10.1038/sj.ki.5001640
  14. Meijers BK, Bammens B, Verbeke K, Evenepoel P. A review of albumin binding in CKD. Am J Kidney Dis 2008;51:839-50. https://doi.org/10.1053/j.ajkd.2007.12.035
  15. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of the protein-bound solute p- cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004;44:278-85. https://doi.org/10.1053/j.ajkd.2004.04.033
  16. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 2005;46:512-9. https://doi.org/10.1053/j.ajkd.2005.05.016
  17. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y. Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003;64:2238-43. https://doi.org/10.1046/j.1523-1755.2003.00310.x
  18. Liabeuf S, Drueke TB, Massy ZA. Protein-bound uremic toxins: new insight from clinical studies. Toxins (Basel) 2011;3:911-9. https://doi.org/10.3390/toxins3070911
  19. Bianchi-Salvadori B, Vesely R, Ferrari A, Canzi E, Casiraghi C, Brighenti F. Behaviour of the pharmaceutical probiotic preparation VSL#3 in human ileostomy effluent containing its own natural elements. New Microbiol 2001;24:23-33.
  20. Brigidi P, Swennen E, Vitali B, Rossi M, Matteuzzi D. PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. Int J Food Microbiol 2003;81:203-9. https://doi.org/10.1016/S0168-1605(02)00245-3
  21. Ranganathan N, Friedman EA, Tam P, Rao V, Ranganathan P, Dheer R. Probiotic dietary supplementation in patients with stage 3 and 4 chronic kidney disease: a 6-month pilot scale trial in Canada. Curr Med Res Opin 2009;25:1919-30. https://doi.org/10.1185/03007990903069249

Cited by

  1. Gut microbiota and inflammation in chronic kidney disease patients vol.8, pp.3, 2015, https://doi.org/10.1093/ckj/sfv026
  2. Resistant starch for modulation of gut microbiota: Promising adjuvant therapy for chronic kidney disease patients? vol.55, pp.5, 2013, https://doi.org/10.1007/s00394-015-1138-0
  3. Methods of reducing the level of indoxyl sulfate - one of the most potent protein-bound uremic toxins vol.35, pp.3, 2013, https://doi.org/10.1080/15569543.2016.1222442
  4. p -Cresyl Sulfate vol.9, pp.2, 2017, https://doi.org/10.3390/toxins9020052
  5. The effects of probiotic supplement on hemoglobin in chronic renal failure patients under hemodialysis: A randomized clinical trial vol.22, pp.6, 2017, https://doi.org/10.4103/jrms.jrms_614_16
  6. Concentrations of representative uraemic toxins in a healthy versus non-dialysis chronic kidney disease paediatric population vol.33, pp.6, 2013, https://doi.org/10.1093/ndt/gfx224
  7. Gut Dysbiosis and the Intestinal Microbiome: Streptococcus thermophilus a Key Probiotic for Reducing Uremia vol.7, pp.8, 2013, https://doi.org/10.3390/microorganisms7080228
  8. Gastrointestinal Microbiota in Patients with Chronic Kidney Disease: A Systematic Review vol.10, pp.5, 2013, https://doi.org/10.1093/advances/nmz028
  9. Indoxyl sulfate associates with cardiovascular phenotype in children with chronic kidney disease vol.34, pp.12, 2013, https://doi.org/10.1007/s00467-019-04331-6
  10. Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis vol.472, pp.3, 2013, https://doi.org/10.1007/s00424-020-02352-x
  11. Pilot Study of Probiotic Supplementation on Uremic Toxicity and Inflammatory Cytokines in Chronic Kidney Patients vol.16, pp.4, 2020, https://doi.org/10.2174/1573401315666190215111402
  12. Intestinal microbiota and diabetic kidney diseases: the Role of microbiota and derived metabolites inmodulation of renal inflammation and disease progression vol.35, pp.3, 2013, https://doi.org/10.1016/j.beem.2021.101484
  13. Chronic Kidney Disease-Associated Itch (CKD-aI) in Children-A Narrative Review vol.13, pp.7, 2013, https://doi.org/10.3390/toxins13070450